References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Genazzani AR, Gadducci A, Gambacciani M. Contro-versial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9–12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001;4: 181–93
- Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecol Endocrinol 2002;16:255–7
- Bush TL, Espeland MA, Mebane-Sims I. The Post-menopausal Estrogen/Progestin Interventions (PEPI) trial: introduction. Control Clin Trials 1995;16(4 Suppl): 1S–2S
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estro gen/Pro ges tin Interventions (PEPI) trial. J Am Med Assoc 1995;273:199–208
- Gambacciani M, Rosano GM, Monteleone P, et al. Clinical relevance of the HERS trial. Lancet 2002; 360(9333):64
- McDonough PG. The randomized world is not with-out its imperfections: reflections on the Women's Health Initiative Study. Fertil Steril 2002;78:951–6
- Bush T. Beyond HERS: some (not so) random thoughts on randomized clinical trials. Int J Fertil Womens Med 2001;46:55–9
- Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women. Baseline data from the Women's Health Initiative. Hypertension 2000;36:780–9